Wolfe Research initiated coverage of Stoke Therapeutics (STOK) with an Outperform rating and $40 price target The firm launched coverage of the neuroscience biotech sector with a “portfolio of high conviction names across multiple therapeutic areas.” Wolfe says Stoke’s STK-001 could be approved as the first disease-modifying therapy for Dravet syndrome.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STOK:
- Stoke Therapeutics participates in a conf call hosted by Cantor Fitzgerald
- Stoke Therapeutics initiated with a Buy at Guggenheim
- Stoke Therapeutics Expands with New Long-Term Waltham Headquarters
- Stoke Therapeutics price target raised to $36 from $32 at Wedbush
- Stoke Therapeutics Accelerates Phase 3 Dravet Study Timeline